MannKind (MNKD) is back in focus after partner United Therapeutics introduced a soft mist inhaler designed to compete with Tyvaso DPI, raising fresh questions around MannKind’s future royalty stream and overall risk profile.

The stock’s 7 day share price return of 40.79% and 30 day share price return of 43.25% follow earnings that paired higher revenue with a quarterly loss, while the United Therapeutics soft mist inhaler news sharply reset sentiment around MannKind’s Tyvaso DPI royalties. This has left its 1 year total shareholder return at 38.58% and suggests that momentum has recently faded.

If this royalty shock has you reassessing healthcare exposure, it could be a good moment to look at 27 healthcare AI stocks as another way to find potential long term ideas in the sector.

With MannKind shares down 41% year to date and the stock trading at a discount to published analyst targets, the key question now is whether the recent selloff has gone too far or if markets are already pricing in future growth.

Most Popular Narrative: 65.9% Undervalued

The most followed narrative sees MannKind’s fair value at $9.61 per share versus a last close of $3.28, and ties that gap to a specific set of revenue, margin and earnings assumptions that stretch out over several years.

Analysts are assuming MannKind's revenue will grow by 13.2% annually over the next 3 years. Analysts assume that profit margins will increase from 10.9% today to 16.1% in 3 years time.

Want to see what kind of earnings profile those revenue and margin targets add up to, and what future multiple is baked into that $9.61 fair value? The full narrative lays out the growth runway, the profit step up and the valuation bridge that need to come together for this pricing gap to close.

Result: Fair Value of $9.61 (UNDERVALUED)

However, there are still clear pressure points, including dependence on Afrezza and Tyvaso DPI and the setback for MNKD-101, that could easily derail this upbeat scenario.

Next Steps

Given the mix of optimism and concern running through this story, it makes sense to move quickly and weigh the full picture for yourself. Start with 3 key rewards and 5 important warning signs.

Looking for more investment ideas?

If this story has sharpened your focus, do not stop here, use the Simply Wall St screener to line up your next set of candidates.

• Target dependable cash generators by scanning companies in our 15 dividend fortresses, which may appeal if regular income is high on your list.
• Hunt for potential mispricings with the screener containing 24 high quality undiscovered gems, built to surface lesser known names with stronger fundamentals than their profiles suggest.
• Prioritize capital protection by reviewing the 74 resilient stocks with low risk scores, which highlights businesses scoring well on our risk checks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.